Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 1, 2015, Pages 72-81

  Zakas, P M ^a   Vanijcharoenkarn, K ^b   Markovitz, R C ^a,b   Meeks, S L ^c   Doering, Christopher B ^c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

Antibody specificity; Cross reactions; Factor VIII; Hemophilia A, acquired; Hemophilia A, congenital

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; EPITOPE; IMMUNOGLOBULIN; PROCOAGULANT; RECOMBINANT BLOOD CLOTTING FACTOR 8; AUTOANTIBODY; BIOLOGICAL MARKER; COAGULATING AGENT; F8 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGENICITY; ARTICLE; BLEEDING; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA A; HUMAN; IMMUNIZATION; IMMUNOREACTIVITY; IN VIVO STUDY; NONHUMAN; ORTHOLOGY; PLASMA; PRIORITY JOURNAL; ANIMAL; BLOOD; BLOOD CLOTTING; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; EPITOPE MAPPING; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; SHEEP; SPECIES DIFFERENCE;

ANIMALS; AUTOANTIBODIES; BIOMARKERS; BLOOD COAGULATION; COAGULANTS; CROSS REACTIONS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNODOMINANT EPITOPES; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT PROTEINS; SHEEP; SPECIES SPECIFICITY;

EID: 84920971123     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12755     Document Type: Article

References (43)

1. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16: 20-32.
2. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CR; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109: 1870-7.
3. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
4. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G III, Lee M. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
5. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
6. Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
7. Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries JE, Hurst D, Bray G, Scandella D. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89: 3663-71.
8. Healey JF, Lubin IM, Nakai H, Saenko EL, Hoyer LW, Scandella D, Lollar P. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995; 270: 14505-9.
9. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000; 95: 564-8.
10. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007; 110: 4234-42.
11. Markovitz RC, Healey JF, Parker ET, Meeks SL, Lollar P. The diversity of the immune response to the A2 domain of human factor VIII. Blood 2013; 121: 2785-95.
12. Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, Lollar P. The humoral response to human factor VIII in hemophilia A mice. J Thromb Haemost 2007; 5: 512-9.
13. Walter JD, Werther RA, Brison CM, Cragerud RK, Healey JF, Meeks SL, Lollar P, Spiegel PC Jr. Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes. Blood 2013; 122: 4270-8.
14. Walter JD, Werther RA, Polozova MS, Pohlman J, Healey JF, Meeks SL, Lollar P, Spiegel PC Jr. Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies. J Biol Chem 2013; 288: 9905-14.
15. Sevy AM, Healey JF, Deng W, Spiegel PC, Meeks SL, Li R. Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry. J Thromb Haemost 2013; 11: 2128-36.
16. Hay CR, DiMichele DM, International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
17. Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P. High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 2002; 277: 38345-9.
18. Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P. Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion. J Biol Chem 2004; 279: 6546-52.
19. Gangadharan B, Parker ET, Ide LM, Spencer HT, Doering CB. High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Blood 2006; 107: 3859-64.
20. Ide LM, Gangadharan B, Chiang KY, Doering CB, Spencer HT. Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood 2007; 110: 2855-63.
21. Doering CB, Gangadharan B, Dukart HZ, Spencer HT. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity. Mol Ther 2007; 15: 1093-9.
22. Dooriss KL, Denning G, Gangadharan B, Javazon EH, McCarty DA, Spencer HT, Doering CB. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A. Hum Gene Ther 2009; 20: 465-78.
23. Doering CB, Denning G, Dooriss K, Gangadharan B, Johnston JM, Kerstann KW, McCarty DA, Spencer HT. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A. Mol Ther 2009; 17: 1145-54.
24. Porada CD, Sanada C, Long CR, Wood JA, Desai J, Frederick N, Millsap L, Bormann C, Menges SL, Hanna C, Flores-Foxworth G, Shin T, Westhusin ME, Liu W, Glimp H, Zanjani ED, Lozier JN, Pliska V, Stranzinger G, Joerg H, et al. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. J Thromb Haemost 2010; 8: 276-85.
25. Zakas PM, Gangadharan B, Almeida-Porada G, Porada CD, Spencer HT, Doering CB. Development and characterization of recombinant ovine coagulation factor VIII. PLoS ONE 2012; 7: e49481.
26. Healey JF, Lubin IM, Lollar P. The cDNA and derived amino acid sequence of porcine factor VIII. Blood 1996; 88: 4209-14.
27. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
28. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood 2008; 112: 1151-3.
29. Barrow RT, Lollar P. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost 2006; 4: 2223-9.
30. Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, Lollar P. The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice. Thromb Haemost 2009; 102: 35-41.
31. Spencer HT, Denning G, Gautney RE, Dropulic B, Roy AJ, Baranyi L, Gangadharan B, Parker ET, Lollar P, Doering CB. Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII. Mol Ther 2011; 19: 302-9.
32. Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia 2006; 6: 23-8; discussion 8-9.
33. Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001; 90: 1-11.
34. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model. J Thromb Haemost 2009; 7: 658-64.
35. Bidwell E. The purification of antihaemophilic globulin from animal plasma. Br J Haematol 1955; 1: 386-9.
36. Macfarlane RG, Mallam PC, Witts LJ, Bidwell E, Biggs R, Fraenkel GJ, Honey GE, Taylor KB. Surgery in haemophilia; the use of animal antihaemophilic globulin and human plasma in thirteen cases. Lancet 1957; 273: 251-9.
37. Biggs R, Macfarlane RG. Treatment of Haemophilia and Other Coagulation Disorders. Oxford: John Wiley and Sons Ltd, 1966.
38. Kernoff PB, Thomas ND, Lilley PA, Matthews KB, Goldman E, Tuddenham EG. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 1984; 63: 31-41.
39. Lollar P. Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules. Haematologica 2000; 85: 26-8.
40. Healey JF, Barrow RT, Tamim HM, Lubin IM, Shima M, Scandella D, Lollar P. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92: 3701-9.
41. Lollar P. Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII. Thromb Haemost 1997; 78: 647-51.
42. Doering C, Parker ET, Healey JF, Craddock HN, Barrow RT, Lollar P. Expression and characterization of recombinant murine factor VIII. Thromb Haemost 2002; 88: 450-8.
43. Sabatino DE, Freguia CF, Toso R, Santos A, Merricks EP, Kazazian HH Jr, Nichols TC, Camire RM, Arruda VR. Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. Blood 2009; 114: 4562-5.